Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 7:14:1124613.
doi: 10.3389/fendo.2023.1124613. eCollection 2023.

Diabetic cardiomyopathy: The role of microRNAs and long non-coding RNAs

Mirjana T Macvanin  1 , Zoran Gluvic  2 , Jelena Radovanovic  1 , Magbubah Essack  3 , Xin Gao  3 , Esma R Isenovic  1
Affiliations
Review

Diabetic cardiomyopathy: The role of microRNAs and long non-coding RNAs

Mirjana T Macvanin et al. Front Endocrinol (Lausanne). .

Abstract

Diabetes mellitus (DM) is on the rise, necessitating the development of novel therapeutic and preventive strategies to mitigate the disease's debilitating effects. Diabetic cardiomyopathy (DCMP) is among the leading causes of morbidity and mortality in diabetic patients globally. DCMP manifests as cardiomyocyte hypertrophy, apoptosis, and myocardial interstitial fibrosis before progressing to heart failure. Evidence suggests that non-coding RNAs, such as long non-coding RNAs (lncRNAs) and microRNAs (miRNAs), regulate diabetic cardiomyopathy-related processes such as insulin resistance, cardiomyocyte apoptosis and inflammation, emphasizing their heart-protective effects. This paper reviewed the literature data from animal and human studies on the non-trivial roles of miRNAs and lncRNAs in the context of DCMP in diabetes and demonstrated their future potential in DCMP treatment in diabetic patients.

Keywords: cardiomyopathy; diabetes; long non-coding RNAs; microRNAs; therapeutic application.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
miRNAs and lncRNAs are implicated in regulating cardiac hypertrophy, apoptosis, and fibrosis. miRNAs are marked in red, whereas lncRNAs are marked in blue color. miRNAs, microRNAs; lncRNA, long non-coding RNAs. Created with Biorender.com.
Figure 2
Figure 2
Therapeutic approaches based on miRNAs and lncRNAs. Non-coding RNAs as therapeutics in diabetes-induced cardiomyopathy. AGO2, Argonaute RISC Catalytic Component 2; ASO, antisense oligonucleotide; DM, diabetes mellitus; RISC, RNA-induced silencing complex; RNAi, RNA interference. Created with BioRender.com.
See this image and copyright information in PMC

References

    1. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. . Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the international diabetes federation diabetes atlas, 9(th) edition. Diabetes Res Clin Pract (2019) 157:107843. doi: 10.1016/j.diabres.2019.107843 - DOI - PubMed
    1. Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord (2010) 11:31–9. doi: 10.1007/s11154-010-9131-7 - DOI - PMC - PubMed
    1. Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: An update of mechanisms contributing to this clinical entity. Circ Res (2018) 122:624–38. doi: 10.1161/circresaha.117.311586 - DOI - PMC - PubMed
    1. Dillmann WH. Diabetic cardiomyopathy. Circ Res (2019) 124 :1160–2. doi: 10.1161/circresaha.118.314665 - DOI - PMC - PubMed
    1. Borghetti G, von Lewinski D, Eaton DM, Sourij H, Houser SR, Wallner M. Diabetic cardiomyopathy: Current and future therapies. beyond glycemic control. Front Physiol (2018) 9:1514. doi: 10.3389/fphys.2018.01514 - DOI - PMC - PubMed

Publication types